This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Apr 5;356(14):1471; author reply 1471-2.

doi: 10.1056/NEJMc070182.

Lapatinib plus capecitabine in breast cancer

PMID: 17409332
DOI: 10.1056/NEJMc070182

Comment

Lapatinib plus capecitabine in breast cancer

Guru Sonpavde. N Engl J Med. 2007.

. 2007 Apr 5;356(14):1471; author reply 1471-2.

doi: 10.1056/NEJMc070182.

Author

PMID: 17409332
DOI: 10.1056/NEJMc070182

No abstract available

PubMed Disclaimer

Comment on

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Geyer CE, et al. N Engl J Med. 2006 Dec 28;355(26):2733-43. doi: 10.1056/NEJMoa064320. N Engl J Med. 2006. PMID: 17192538 Clinical Trial.

Similar articles

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Geyer CE, et al. N Engl J Med. 2006 Dec 28;355(26):2733-43. doi: 10.1056/NEJMoa064320. N Engl J Med. 2006. PMID: 17192538 Clinical Trial.
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B, Benekli M, Turker I, Koral L, Ulas A, Dane F, Oksuzoglu B, Kaplan MA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Cetin B, et al. J Chemother. 2014 Oct;26(5):300-5. doi: 10.1179/1973947813Y.0000000147. Epub 2013 Dec 6. J Chemother. 2014. PMID: 24112786
Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.
Cameron D. Cameron D. Clin Adv Hematol Oncol. 2007 Jun;5(6):456-8. Clin Adv Hematol Oncol. 2007. PMID: 17679920 Clinical Trial. No abstract available.
[Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
Ismaili N, Belbaraka R, Elomrani A, Khouchani M, Tahri A. Ismaili N, et al. Presse Med. 2013 Nov;42(11):1461-8. doi: 10.1016/j.lpm.2013.01.066. Epub 2013 May 27. Presse Med. 2013. PMID: 23721860 Review. French.
Lapatinib in metastatic breast cancer.
Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M. Frenel JS, et al. Womens Health (Lond). 2009 Nov;5(6):603-12. doi: 10.2217/whe.09.54. Womens Health (Lond). 2009. PMID: 19863462 Review.

See all similar articles

Cited by

Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
Frampton JE. Frampton JE. Drugs. 2009 Oct 22;69(15):2125-48. doi: 10.2165/11203240-000000000-00000. Drugs. 2009. PMID: 19791830 Review.
N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway.
Li X, Wang S, Deng N, Guo X, Fu M, Ma Y, Sun T. Li X, et al. Oxid Med Cell Longev. 2022 Apr 27;2022:8123120. doi: 10.1155/2022/8123120. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35528507 Free PMC article.
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer.
Salkeni MA, Rizvi W, Hein K, Higa GM. Salkeni MA, et al. Breast Cancer (Dove Med Press). 2021 Sep 24;13:539-557. doi: 10.2147/BCTT.S288344. eCollection 2021. Breast Cancer (Dove Med Press). 2021. PMID: 34602823 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information